hero image

Telerx to Acquire C3i, a Life Science Technology Services and Solutions Provider, Adding Global Capabilities

HORSHAM, Pa., May 27 – Telerx, a leader in U.S. customer care services, today announced that it has signed an agreement to acquire C3i, a leading provider of technology support services for the life sciences industry. This acquisition will add to Telex’s existing programs in support of their pharmaceutical business and enable it to support clients in their local markets outside of the U.S. Current Telerx domestic and C3i global operations will not be immediately impacted.

C3i serves more than half of the world’s largest pharmaceutical companies from five global operations centers, delivering 24/7 global, multi-lingual service desk support, end-user training and hardware provisioning services.

“Telerx and C3i have a deep understanding of the unique demands of the global pharmaceutical industry and have worked to develop state-of-the-art services and solutions to help clients achieve their goals,” said Linda Schellenger, president of Telerx. “We look forward to fully integrating C3i and Telerx, and to expanding our footprint to support our clients regardless of language or time zone.”

“Together, C3i and Telerx will have an opportunity to take our existing services to the next level and meet the growing global demand for sophisticated solutions to complex healthcare processes,” said Joel H. Morse, CEO and co-founder of C3i.

The parties expect to close the transaction during the second quarter of 2014.

About Telerx
Telerx, a subsidiary of Merck & Co, Inc., offers complete management of complex and sensitive interactions in the healthcare marketplace, including access and reimbursement, pharmacovigilance, product recalls and critical events, quality and compliance, and patient assistance, among others. The company adheres to strict regulatory requirements and standard operating procedures related to the pharmaceutical industry. More than 90 percent of the company’s clients are FDA-regulated. Telerx has corporate headquarters in Horsham, Pa., with additional contact centers in Allentown and Wilkes-Barre, Pa.; El Paso, Texas; Kings Mountain, N.C.; and Little Falls, N.J. For more information, visit Telerx.com or connect via Facebook, Twitter and LinkedIn.

About C3i
Headquartered in Morristown, N.J., C3i Inc. has global operations in North America, Europe, India and China. Its 1,500 employees provide technology training, multi-lingual service desk, hardware provisioning, and break/fix, asset management and user/application administration services for pharmaceutical sales and clinical professionals worldwide. To learn more, visit www.c3i-inc.com.

About Merck
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
For Media Inquiries:
Ela Voluck
For Telerx